| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Marker Therapeutics, Inc.$1.51
-0.07 (-4.43%)
D 35Pipeline Score Undervalued Biotech · Commercial
Market Cap
23.34 M
EPS
-0.67
P/E Ratio
-
Value Trade
38.03 K
SEC Financials
Q1 2026Dilution Risk
Revenue
751.69 K
R&D Expenses
2.84 M
Operating CF
-1.40 M
Total Assets
17.43 M
Total Liabilities
3.64 M
Equity
13.80 M
D/E Ratio
12,345
-3.45 %
Week
-12.5 %
1 Month
-5.41 %
3 Month
37.25 %
6 Month
-94.55 %
5 Year
-100 %
All Time
Cash Data
Cash Position
14.92 M
Monthly Burn
468.00 K
Runway
30.3 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
70.90 K
52 Week Range
0.81 - 4.07
% held by Insiders
19.03 %
% held by Institutions
10.33 %
Enterprise Value
7.70 M
Total Shares
16.66 M
Short %
0.9 %
Float Shares
12.91 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Marker Therapeutics, Inc.
276Total events
3Upcoming
58Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 3
Event history 273
Q2 2026
◆Topline ReadoutMT-601Clinical Data
Data update from APOLLO study in DLBCL expected in Q2 2026
relapsed Diffuse Large B Cell Lymphoma (DLBCL)source ↗
Feb 25, 2026
◆Oral PresentationPresentation
CEO Dr. Juan Vera to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Jan 22, 2026
▲Oral PresentationPresentation
Baylor TACTOPS study featured on Good Morning America
pancreatic cancersource ↗
Jan 5, 2026
▲Full ResultsClinical Data
Publication of Phase 1/2 results of Multi-Antigen Targeted T cells in pancreatic cancer in Nature Medicine
pancreatic cancersource ↗
Jan 2026
▲PublicationPresentation
Nature Medicine publication on MAR-T cells in pancreatic cancer
pancreatic cancersource ↗
Q1 2026
◆Trial InitiationTrial
Clinical initiation of pancreatic cancer program with MAR-T cells
pancreatic cancersource ↗
Dec 8, 2025
◆Poster PresentationMT-601Presentation
MT-601 Demonstrates Favorable Safety and Durable Responses in r/r NHL poster at ASH
relapsed or refractory Non-Hodgkin lymphomasource ↗
Dec 6, 2025
◆Poster PresentationMT-601Presentation
Safety and Efficacy of MT-601 in r/r Hodgkin Lymphoma poster at ASH
relapsed or refractory Hodgkin lymphomasource ↗
Nov 14, 2025
▲Topline ReadoutMT-601Clinical Data
APOLLO study showed 66% ORR, 50% CR in NHL patients
relapsed/refractory B-cell lymphoma (Non-Hodgkin lymphoma)source ↗
Nov 3, 2025
▲Enrollment MilestoneMT-601Trial
Advanced to dose expansion phase at highest dose level (400x10^6 cells) in DLBCL patients
Diffuse Large B Cell Lymphoma (DLBCL) relapsed after anti-CD19 CAR-T or ineligiblesource ↗
Drug Pipeline Intelligence
D35
Pipeline Score $86M
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored3.7x
rNPV / MCap Top 47%
Micro Cap (rank 484 of 911)
Percentile RankMarker Therapeutics, Inc. faces pipeline headwinds (35/100), with $343M risk-adjusted pipeline value, led by Low dose FRα vaccine in Breast Cancer (Phase 2), across $55B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low dose FRα vaccine Monoclonal antibody | Breast Cancer | Phase 2 | NCT02593227 | 14% | $118M | COMPLETED | 80 | - | - | Jul 15, 2021 | - | Jul 19, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MT-601 | relapsed non-Hodgkin lymphoma | Phase 1 | 2026-03-18 | objective response rate: 66%; complete responses: 50% | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, includi Read More | |
MT-601 | relapsed non-Hodgkin lymphoma | Phase 1 | 2026-03-18 | objective response rate: 66%; complete responses: 50% | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, includi Read More | |
MT-601 | relapsed non-Hodgkin lymphoma | Phase 1 | 2026-03-18 | objective response rate: 66%; complete responses: 50% | Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, includi Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MRKR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MRKR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MRKRMarker Therapeutics Reports Year-End 2025 Corporate and Financial Results Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, includi
Marker Therapeutics, Inc. reported their 2025 corporate and financial results, highlighting encouraging clinical activity in their Phase 1 APOLLO study where a 66% objective response rate was achieved in relapsed non-Hodgkin lymphoma. The company also announced promising research in pancreatic cancer using their multi-antigen recognizing T cell therapy. They noted an increase in net loss compared to the previous year and emphasized the importance of upcoming data updates and the initiation of new clinical programs over the next 12 to 18 months.
Read more →MRKRMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Marker Therapeutics, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Dr. Juan Vera will lead the presentation and participate in one-on-one meetings with investors. The company focuses on developing T cell-based immunotherapies for various cancers and has demonstrated promising results in clinical trials.
Read more →MRKR▼ -11%on this news· ran to -23% by day 3
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
Marker Therapeutics announced that Baylor College of Medicine's pancreatic cancer study utilizing MAR-T cell technology was featured on Good Morning America. The study, published in Nature Medicine, showed promising results in treating pancreatic ductal adenocarcinoma. Marker plans to build on these results in an upcoming study, aiming to improve patient outcomes further.
Read more →MRKR▲ +16.2%on this news· ran to +34% by day 3
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Baylor College of Medicine's clinical study shows promising results for Multi-Antigen Targeted T cells in pancreatic cancer, achieving an 84.6% disease control rate. The study indicates a favorable safety profile and a median overall survival of 14.1 months. Marker Therapeutics plans to enhance this therapy further and initiate a pancreatic cancer program in 2026.
Read more →MRKRMarker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601
Marker Therapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting promising outcomes from the ongoing APOLLO study of MT-601 for relapsed B-cell lymphoma. The study showed a 66% objective response rate and a notable 50% complete response rate in heavily pre-treated patients. Additionally, the company announced a strategic collaboration with Cellipont Bioservices to enhance production capabilities. Financially, Marker Therapeutics raised approximately $10 million, extending its cash runway into 2026, despite posting a net loss of $2.0 million for the quarter.
Read more →MRKRMarker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Marker Therapeutics has appointed Kathryn Penkus Corzo to its Board of Directors, effective November 1, 2025. With over 30 years of experience in biopharma, Ms. Corzo's expertise will support the company's clinical and corporate objectives, particularly in advancing the APOLLO program for CAR-relapsed DLBCL. The MAR-T cell platform aims to enhance treatment options for patients.
Read more →MRKRMarker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Marker Therapeutics announced that data from the Phase 1 APOLLO study of MT-601 will be presented at the 67th ASH Annual Meeting. The study showed encouraging efficacy and a strong safety profile, with high objective response rates in patients with relapsed Non-Hodgkin and Hodgkin lymphoma. The company is advancing to the dose expansion phase for further evaluation.
Read more →MRKR▲ +13.1%on this news
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics has successfully treated the first patient in its Off-the-Shelf (OTS) program as part of the Phase 1 RAPID study. The initial dose of the MAR T cell product was well tolerated, showing no adverse events. The program aims to expedite treatment for patients with acute myeloid leukemia and myelodysplastic syndromes, leveraging commercially available leukapheresis material for faster manufacturing.
Read more →MRKRMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Marker Therapeutics, Inc. will have its CEO, Dr. Juan Vera, participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The event will include discussions on the company's Multi-Antigen Recognizing T cell platform and recent updates on the Phase 1 APOLLO study. Investors can register for the event online.
Read more →MRKR▼ -20.6%on this newsshared move
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Marker Therapeutics has reported encouraging results from its Phase 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma. The study demonstrated a 66% objective response rate and a 50% complete response rate among Non-Hodgkin Lymphoma patients. No dose limiting toxicities were observed, and the safety profile was favorable. The trial will proceed to a dose expansion phase to further evaluate MT-601's efficacy.
Read more →MRKRMarker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics, Inc. will have its CEO, Dr. Juan Vera, participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference from August 12-14, 2025. The event will focus on the company's Multi-Antigen Recognizing T cell platform and its clinical developments. Investors can register to view the event online.
Read more →MRKRMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics has partnered with Cellipont Bioservices to enhance the cGMP manufacturing of MT-601, a T cell therapy for lymphoma patients. This collaboration aims to support the ongoing Phase 1 APOLLO study, which has shown promising results with a significant response rate. The partnership is expected to facilitate future pivotal trials and commercial readiness for MT-601.
Read more →MRKRMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Marker Therapeutics reported that lymphodepletion enhances the expansion and persistence of MAR-T cells in lymphoma patients. The Phase 1 APOLLO study shows promising results, with 78% of patients achieving objective responses. The company anticipates a significant increase in clinical data as patient enrollment accelerates. A clinical data readout is expected later this year.
Read more →MRKRMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
Marker Therapeutics, Inc. will feature its MAR-T cell therapy platform during a live webcast on May 28, 2025. CEO Dr. Juan Vera will discuss the advantages of this non-engineered multi-antigen approach compared to traditional CAR-T therapies. The event will include a roundtable with prominent experts in the cancer treatment field, aiming to address the effectiveness of CD19 CAR-T cells since their FDA approval.
Read more →MRKR▼ -7.3%on this news· ran to -19% by day 3
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
Marker Therapeutics, Inc. announced that CEO Dr. Juan Vera will participate in a panel at Canaccord Genuity's Horizons in Oncology Virtual Conference. The discussion will focus on innovations in T cell-based immunotherapies, particularly CAR-T and novel approaches in treating solid tumors. The company's MAR-T cell therapy platform aims to target multiple tumor-associated antigens, demonstrating promising results in clinical trials.
Read more →MRKRMarker Therapeutics Reports Year-End 2024 Corporate and Financial Results Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy
Marker Therapeutics has reported its year-end 2024 corporate and financial results, highlighting the promising safety and efficacy of its lead therapy, MT-601, in treating refractory lymphomas. The therapy showed a 78% objective response rate in a preliminary Phase 1 study. Additionally, the company secured over $13 million in non-dilutive funding to further support its clinical programs. However, Marker also reported a net loss of $10.7 million for the fiscal year, up from $8.2 million in 2023.
Read more →MRKR▼ -7.4%on this news
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demon
Marker Therapeutics provided an update on the Phase 1 APOLLO study for MT-601, a T cell therapy for relapsed lymphoma patients. The study reported a significant objective response rate of 78%, with 44.4% of patients achieving a complete response. MT-601 was well tolerated among participants, with no severe side effects noted. This promising data comes as an important option for patients who have had limited treatment alternatives after anti-CD19 CAR-T therapies.
Read more →MRKR▲ +17.7%on this newsshared move
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer Houston, TX
Marker Therapeutics has secured a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance its clinical investigation of MT-601 in patients with metastatic pancreatic cancer. The grant will specifically support the Phase 1 PANACEA study, which aims to evaluate the safety and tolerability of the treatment. MT-601 is designed to target multiple tumor-associated antigens, and prior studies show promising safety and efficacy results. The funding adds to the over $30 million in non-dilutive financing the company has received from various governmental sources since its inception.
Read more →MRKRMarker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical inve
Marker Therapeutics, Inc. reported its financial results for Q3 2024, highlighting progress in its clinical programs. The company received two $2 million grants from the NIH to aid in the development of MT-601 for lymphoma and pancreatic cancer. The ongoing Phase 1 APOLLO trial is showing encouraging results, and preliminary data is expected by the end of 2024. Despite a reduction in its net loss compared to the prior year, Marker faces increasing operational costs and a notable decrease in cash reserves.
Read more →MRKRMarker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in
Marker Therapeutics reported positive outcomes in its Phase 1 APOLLO study, showing preliminary safety and efficacy for MT-601 in lymphoma patients. The treatment demonstrated no observed significant side effects, and the company secured a $2 million NIH grant for further investigation. Financial results for Q2 2024 reflect a reduced net loss compared to the previous year, aided by recent restructuring efforts. The company aims to continue advancing its clinical programs while managing cash flow carefully.
Read more →MRKRMarker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma Marker Therapeutics to receive non-dilutive funding from NIH Sma
Marker Therapeutics has received a $2 million grant from the NIH to support a Phase 1 study of MT-601, aimed at CAR-relapsed patients with non-Hodgkin's lymphoma. The grant, awarded through the SBIR program, recognizes the preliminary clinical and non-clinical data showcasing MT-601's effectiveness. This funding will be used for the nationwide multi-center APOLLO trial to investigate MT-601's safety and efficacy further. The company has accrued over $19 million in non-dilutive funding to date, underscoring its innovative approach to treatment.
Read more →MRKRMarker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in
Marker Therapeutics reported strong Q1 2024 results, highlighting preliminary safety and efficacy of MT-601 in lymphoma patients from the Phase 1 APOLLO study. One participant achieved a complete response, lasting nine months post-treatment. Furthermore, the company announced the approval of 'neldaleucel' as the nonproprietary name for MT-601, suggesting progress toward market readiness. Financially, the company reported a reduced net loss, positioning itself well for future clinical developments.
Read more →MRKRPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11 th Global Summit on Hematologic Malignancies Preliminary data from study in pa
Marker Therapeutics' Principal Investigator Geoffrey Shouse presented findings from the Phase 1 APOLLO study on MT-601 at the 11th Global Summit on Hematologic Malignancies. Preliminary data revealed that lymphoma patients, including those with a history of CAR T cell therapy failures, responded well to MT-601 with one participant maintaining a complete response for nine months. The treatment was well-tolerated with no significant adverse effects reported. This trial is designed to evaluate the safety and efficacy of MT-601 in relapsed or refractory lymphoma patients, with encouraging initial results prompting hopes for expanded enrollment.
Read more →MRKRMarker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study partic
Marker Therapeutics has reported its year-end 2023 results, highlighting the preliminary safety and efficacy of MT-601 in lymphoma patients. The company secured $2 million in non-dilutive funding from the NIH to advance its AML program and received Orphan Drug Designation for MT-401 from the EMA. Additionally, significant operational changes and financial measures are expected to extend the company's cash runway into 2025. Overall, Marker aims to continue its strategic focus on innovative T cell therapies for cancer treatment.
Read more →MRKRMarker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstra
Marker Therapeutics, Inc. has announced a restructuring of its clinical programs with a strategic focus on its multiTAA-specific T cell therapies, particularly MT-601 for lymphoma patients and MT-401 for those with MRD+ AML. The company reported positive clinical data indicating the safety and efficacy of these treatments while addressing significant unmet medical needs. The restructuring aims to enhance treatment availability and accelerate the commercial development of these therapies, particularly through a new manufacturing approach that could reduce patient wait times to as little as 72 hours.
Read more →MRKR▲ +46.9%on this news· ran to +58% by day 3
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse Study participant with Non-Hodgkin's Lymphoma who relapsed after anti-CD19 CAR T cell therap
Marker Therapeutics has reported a sustained complete response in the first patient treated with MT-601 in the APOLLO study, showing promising outcomes for a patient with diffuse large B cell lymphoma who previously relapsed after anti-CD19 CAR T cell therapy. Six months post-treatment, the patient remains in complete response, suggesting the potential durability of MT-601 compared to traditional CAR T therapies. The study indicates that MT-601, utilizing a novel non-genetically modified approach, could be a viable alternative for lymphoma patients with limited options. Marker Therapeutics aims to continue the study with more participants to validate these encouraging results.
Read more →MRKRMarker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relaps
Marker Therapeutics, Inc. reported its third quarter 2023 financial results, highlighting a complete response in the first patient with lymphoma treated with its MT-601 therapy in the Phase 1 APOLLO trial. The company also received Orphan Drug Designation for its MT-401 product candidate aimed at treating Acute Myeloid Leukemia. Despite positive developments in clinical outcomes and future trial plans, the company reported a net loss of $2.98 million for the quarter, with rising operating expenses year-over-year.
Read more →MRKR▲ +11.4%on this news
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who ha
Marker Therapeutics has announced a complete response in the first patient treated with its MT-601 therapy in the APOLLO trial, targeting lymphoma patients who have relapsed following anti-CD19 CAR T cell therapy. The patient, who had previously undergone four lines of treatment, showed significant improvement after receiving two doses of MT-601 at a 200 million cell dose level. Notably, the treatment was well tolerated, with no serious adverse events observed, marking a promising step in MT-601's development for challenging lymphoma cases.
Read more →MRKRMarker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Executed comprehensive non-dilutive agreement with Cell Ready TM , resulting in an extended financial runway into the fourth
Marker Therapeutics reported positive financial results and significant corporate updates for Q2 2023. The company executed a non-dilutive agreement with Cell Ready, extending its financial runway into the fourth quarter of 2025. New leadership has commenced efforts to advance clinical trials, with encouraging non-clinical data for its MT-401 program in AML and the initiation of patient treatment with MT-601 in lymphoma. Additionally, Marker received a $2 million grant from the NIH to support their therapies.
Read more →MRKRMarker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program Houston, TX
Marker Therapeutics announced promising non-clinical proof-of-concept data for its MT-401 Off-the-Shelf (OTS) T cell product, showing significant anti-tumor activity against the THP-1 acute myeloid leukemia cell line. The U.S. FDA has cleared the protocol for clinical trials, and MT-401 OTS is expected to begin patient treatments in the first half of 2024. This approach uses a partially HLA-matched strategy, which could simplify manufacturing and enhance patient access to treatment. The overall strategy aims to address significant bottlenecks in current cell therapies and improve treatment options for relapsed/refractory AML.
Read more →MRKR▲ +23%on this news
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients Houston, TX
Marker Therapeutics has announced that the European Medicines Agency has granted Orphan Drug Designation for its T cell therapy, MT-401, aimed at treating acute myeloid leukemia (AML). This designation recognizes the urgent need for innovative treatments in a condition characterized by high relapse rates and poor outcomes. The T cell therapy is currently undergoing a Phase 2 clinical trial and targets multiple tumor antigens, potentially reducing relapse risk in patients post-stem cell transplant. As an orphan drug, MT-401 will benefit from expedited development and support from regulatory authorities.
Read more →MRKR▼ -6.6%on this news· ran to -28% by day 3
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration Marker Therapeutics Awarded $2 Million Grant from NIH in Support of the Development of MT-401 for the Treatment
Marker Therapeutics has reported positive non-clinical data indicating that its lead product candidate, MT-401, exhibits increased anti-tumor activity in AML cells following treatment with hypomethylating agents. The company has also secured a $2 million SBIR grant from the NIH aimed at supporting a multi-center Phase 2b clinical trial for MT-401. The trial will evaluate the efficacy and safety of MT-401 in AML patients who have undergone hematopoietic stem cell transplantation. The findings from an in vitro study will be integrated into their ongoing clinical research efforts to enhance treatment outcomes for patients with AML.
Read more →MRKR▲ +19.5%on this news
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial Marker Therapeutics initiated APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T
Marker Therapeutics has initiated the APOLLO trial, treating the first lymphoma patient with MT-601, a novel T cell therapy targeting multiple tumor-associated antigens. This Phase 1 trial aims to evaluate the safety and preliminary efficacy of MT-601 in patients who have relapsed after or are ineligible for anti-CD19 CAR T cell therapy. Initial results indicate that the therapy is well tolerated, suggesting a favorable safety profile. The trial will gather crucial data that may influence the future development of MT-601 in treating lymphoma.
Read more →MRKR▲ +33.8%on this news
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells MT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro Houston, TX
Marker Therapeutics announced promising pre-clinical data for its MT-601 multiTAA-specific T cell product candidate targeting lymphoma cells. The therapy demonstrated anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro. The company has begun a Phase 1 clinical trial evaluating MT-601 in patients who have relapsed after or are ineligible for anti-CD19 CAR T cell treatment. Marker believes that the multiTAA approach could lead to more durable responses compared to conventional therapies.
Read more →MRKR▲ +16%on this news
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer Accomplished healthcare executive brings extensive drug development and regulatory experience from global pharmaceutical companies to Marker Thera
Marker Therapeutics has appointed Monic Stuart, M.D., as its new Chief Medical Officer, bringing over 20 years of experience in drug development and clinical strategy. Dr. Stuart will focus on advancing the company's T cell-based immunotherapy programs targeting hematological malignancies. Her background in treating acute myeloid leukemia and lymphoma aligns with Marker's priorities as it continues the MT-401 Phase 2 clinical study. The appointment is seen as a strategic move to leverage her expertise in progressing the company's specialized therapies.
Read more →MRKR▲ +16.5%on this news· ran to +81% by day 3
MARKER THERAPEUTICS announces comprehensive non-dilutive AGREEMENT WITH CELLREADY STRUCTURED TO EXTEND MARKER'S FINANCIAL RUNWAY THROUGH YEAR-END 2025 MaRKER Announces LeADERSHIP TRANSITION & ProVIdes
Marker Therapeutics has announced a comprehensive non-dilutive agreement with CellReady that will enhance its financial resources until the end of 2025. This arrangement involves the sale of certain manufacturing assets for $19 million in cash, helping to reduce annual operational costs. Concurrently, Marker has undergone a leadership transition with Dr. Vera assuming the CEO role and is focusing on advancing its clinical programs, particularly MT-601 and MT-401, aimed at treating specific malignancies. The strategic steps are aimed at bolstering Marker’s operational capabilities without diluting shareholder value.
Read more →MRKR▼ -31.8%on this news· ran to -54% by day 3
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results 2022 CLINICAL AND REGULATORY HIGHLIGHTS Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of
Marker Therapeutics, Inc. reported its fiscal year 2022 results, highlighting significant advancements in its clinical programs, particularly the MT-401 Phase 2 ARTEMIS trial targeting acute myeloid leukemia (AML). The company secured a $2 million FDA grant and reported encouraging preliminary data in measurable residual disease (MRD) positive patients. While the financial report showed a reduced net loss compared to 2021, concerns about cash reserves were noted, with existing funds expected to last through Q3 2023. The firm also announced progress in other programs, including receiving FDA IND clearances for non-Hodgkin lymphoma and pancreatic cancer treatments.
Read more →MRKRMarker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million Houston, TX
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million Houston, TX- December 13, 2022-Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation
Read more →MRKRMarker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer Houston, TX
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer Houston, TX- November 22, 2022-Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the developmen
Read more →MRKRMarker Therapeutics Reports Q3 2022 Operating and Financial Results Company awarded $2 million U.S. FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of its lead T cell therapy candidate MT-401 in patients with
Marker Therapeutics Reports Q3 2022 Operating and Financial Results Company awarded $2 million U.S. FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of its lead T cell therapy candidate MT-401 in patients with post-transplant AML Houston, TX- November 10, 2022-Mark
Read more →MRKR▲ +7.1%on this news
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML Award to fund clinical study of Marker's multi-antigen targeted T cell therapy for the
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML Award to fund clinical study of Marker's multi-antigen targeted T cell therapy for the treatment of post-transplant AML patients with minimal r
Read more →MRKR▼ -8.1%on this news· ran to -25% by day 3
Marker Therapeutics Reports Q2 2022 Operating and Financial Results Houston, TX
Marker Therapeutics Reports Q2 2022 Operating and Financial Results Houston, TX- August 11, 2022-Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment
Read more →MRKRMarker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma Company expects to initiate Phase 1 trial of MT-601 in
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023 Houston, TX-August 4, 2022-Marker Thera
Read more →MRKRMarker Therapeutics Reports Q1 2022 Operating and Financial Results Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year
Marker Therapeutics Reports Q1 2022 Operating and Financial Results Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 Hous
Read more →MRKRMARKER THERAPEUTICS ANNOUNCES ENTRY INTO SERVICES AGREEMENT WITH WILSON WOLF HOUSTON, April 26 , 2022 (GLOBE NEWSWIRE) -- -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing
MARKER THERAPEUTICS ANNOUNCES ENTRY INTO SERVICES AGREEMENT WITH WILSON WOLF 2022 (GLOBE NEWSWIRE) -- -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the t
Read more →MRKRMarker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results Enrollment of first 20 patients of the Company's Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 act
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results Enrollment of first 20 patients of the Company's Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated Company plans to file INDs in l
Read more →MRKRMarker Therapeutics Announces Clinical Program Updates and Pipeline Expansion Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual dis
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced New T cell m
Read more →MRKRMarker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer Houston, TX
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer TX -January 19, 2022 - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generat
Read more →MRKRMarker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors Houston, TX
Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors Houston, TX -December 9, 2021- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunot
Read more →MRKRMarker Therapeutics Reports Third Quarter 2021 Operating and Financial Results Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021 Topline readout of Group 2 active disease anticipat
Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results Enrollment of first 20 patients of the Company's Phase 2 AML trial anticipated in Q4 2021 Topline readout of Group 2 active disease anticipated Company to host year-end conference call and Housto
Read more →MRKR▼ -5.1%on this news
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas Houston, TX
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas Houston, TX-August 19, 2021-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-ba
Read more →MRKRMarker Therapeutics Reports Second Quarter 2021 Operating and Financial Results Marker continues to enroll patients and activate clinical sites in Phase 2 AML trial following completion of safety lead-in Company's new in
Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results Marker continues to enroll patients and activate clinical sites in Phase 2 AML trial following completion of safety lead-in Company's new in-house cGMP manufacturing facility in Houston is fully
Read more →MRKRMarker Therapeutics Announces Opening of New cGMP Manufacturing Facility Facility is now available to manufacture study drug, MT-401, for Marker's Phase 2 AML trial Houston, TX
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility Facility is now available to manufacture study drug, MT-401, for Marker's Phase 2 AML trial Houston, TX-July 28, 2021-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company sp
Read more →MRKRMarker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML Company continues to enroll patients in main portion of the Phase 2 trial with topline data from active disease g
Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML Company continues to enroll patients in main portion of the Phase 2 trial with topline data from active disease group expected in Q1 2022 2021-Marker Therapeutics, Inc.
Read more →MRKRMarker Therapeutics Reports First Quarter 2021 Operating and Financial Results Marker continues to advance Phase 2 AML trial, recently dosing first patient Company closed financing extending cash runway into Q1 2023 Comp
Therapeutics Reports First Quarter 2021 Operating and Financial Results continues to advance Phase 2 AML trial, recently dosing first patient closed financing extending cash runway into Q1 2023 to host conference call and webcast today at 5:00 p.m. ET TX-May 12, 2021-Marker T
Read more →MRKRCORPORATE PRESENTATION March 2021 FORWARD LOOKING STATEMENTS Certain statements contained herein are forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and
CORPORATE PRESENTATION March 2021 FORWARD LOOKING STATEMENTS Certain statements contained herein are forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Exchange Act of 1934, as amen
Read more →MRKRMarker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results - Dosed first patient in the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results Houston, TX-March 9, 2021-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the tre
Read more →MRKRMarker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant Topline readout of active disease group in AML trial expected in Q1 2022 Houston,
Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant Topline readout of active disease group in AML trial expected in Q1 2022 Houston, TX - March 3, 2021- Marker Therapeutics, Inc. (NASDAQ:MRKR), a
Read more →MRKRMarker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates - Company expects to complete tech transfer and treat first pa
Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates Houston, TX - January 13, 2021 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company spec
Read more →MRKRMarker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial Houston, TX
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial Houston, TX-January 5, 2021-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunothe
Read more →MRKRMarker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - Initiated first Marker-sponsored study, a Phase 2 trial of MT-401 for the treatment of post-transplant acute myeloid leukemia, and enrolled
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results first Marker-sponsored study, a Phase 2 trial of MT-401 for the treatment of post-transplant acute myeloid leukemia, and enrolled the first patient in the safety lead-in portion - - Received altern
Read more →MRKRMarker Therapeutics Reports Second Quarter 2020 Operating and Financial Results Houston, TX
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results Houston, TX-August 10, 2020-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for th
Read more →MRKRMarker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates - Facility expected to be built by year-end, fully operational in 2021 - Hou
Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates Houston, TX - June 30, 2020 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the d
Read more →MRKRMarker Therapeutics Receives USAN Approval for " zelenoleucel " as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia Houston, TX
Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia Houston, TX - June 23, 2020 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-on
Read more →MRKRPhase 1 Trial in Pancreatic
Phase 1 Trial in Pancreatic Adenocarcinoma (TACTOPS) JUNE 1, 2020 FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future r
Read more →MRKRMarker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2 020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting - Results de
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Oncology (ASCO) Virtual Annual Meeting - Results demonstrate potential of MultiTAA-specific T cell therapy in combination with c
Read more →MRKRMarker Therapeutics Reports First Quarter 2020 Operating and Financial Results Company to host conference call and webcast today at 5:00pm EDT Houston, TX
Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results Company to host conference call and webcast Houston, TX-May 11, 2020-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-genera
Read more →MRKRMarker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia Houston, TX
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia TX-April 29, 2020-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generat
Read more →MRKRMarker Therapeutics Reports Full Year 2019 Operating and Financial Results Houston, TX
Marker Therapeutics Reports Full Year 2019 Operating and Financial Results TX-March 12, 2020-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of he
Read more →MRKRMarker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million Houston, TX
Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million Houston, TX - March 2, 2020- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based imm
Read more →MRKRMarker Therapeutics Announces Update to its Clinical Program in AML U.S. FDA lifts clinical hold on Phase 2 AML trial; places partial hold on the trial for the use of a reagent from an alternative vendor until final data
Therapeutics Announces Update to its Clinical Program in AML FDA lifts clinical hold on Phase 2 AML trial; places partial hold on the trial for the use of a reagent from an alternative vendor until final data and certificate of analysis are accepted by FDA Houston, TX - Februa
Read more →MRKRMarker Therapeutics Reports Third Quarter 2019 Operating and Financial Results Conference Call and Webcast Today at 5:00pm EST Houston, TX
Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results Conference Call and Webcast Today Houston, TX - November 12, 2019 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generat
Read more →MRKRLYMPHOMA PHASE I TRIAL (TACTAL) Group A: Active disease (15 patients) 7 complete responses (CR) Durable for 4 months -- >5 years No patient achieving a CR has subsequently relaps
6 LYMPHOMA PHASE I TRIAL (TACTAL) Group A: Active disease (15 patients) 7 complete responses (CR) Durable for 4 months -- >5 years No patient achieving a CR has subsequently relapsed 8 stable disease (SD) Durable for 4 -- >12 months) 2 patients subsequently achieved CR with confo
Read more →MRKRMarker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs Houston, TX
Marker Therapeutics Appoints Nadia Agopyan, Vice President of Regulatory Affairs Houston, TX - August 15, 2019 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies f
Read more →MRKRMarker Therapeutics Reports Second Quarter 2019 Operating and Financial Results Houston, TX
Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results TX-August 8, 2019-Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment
Read more →MRKRMarker Therapeutics Appoints Steve Elms to its Board of Directors Houston, TX
Marker Therapeutics Appoints Steve Elms to its Board of Directors Houston, TX - August 6, 2019 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment
Read more →MRKRJuly 22 nd 2019 Peter Hoang President & Chief Executive Officer 1 2 3 Brandon G. Smaglo M.D., FACP Lead investigator and Assistant Professor of Oncology at Baylor College of Medicine 4 5 6 7 8 9 10 11 12 13 14 15 16 17 1
Peter Hoang President & Chief Executive Officer Brandon G. Smaglo M.D., FACP Lead investigator and Assistant Professor of Oncology at Baylor College of Medicine
Read more →MRKRMarker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma Data selected for oral presentation during a plenary session at AACR's Immune Cell Thera
Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma Data selected for oral presentation during a plenary session at AACR's Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells
Read more →MRKRMarker Therapeutics Reports First Quarter 2019 Operating and Financial Results -Company on track to submit IND for Phase 2 AML clinical trial in the third quarter, with first patient enrolled by year end- -MultiTAA T cel
Therapeutics Reports First Quarter 2019 Operating and Financial Results on track to submit IND for Phase 2 AML clinical trial in the third quarter, with first patient enrolled by year end- T cell therapies continue to generate positive clinical results across various indication
Read more →MRKRMarker Therapeutics Provides Business and Clinical Update -MultiTAA T cell therapies continue to demonstrate positive clinical data across multiple indications in investigator-sponsored trials- -Marker plans IND submissi
Therapeutics Provides Business and Clinical Update T cell therapies continue to demonstrate positive clinical data across multiple indications in investigator-sponsored trials- plans IND submission for Company-sponsored Phase 2 AML study in the third quarter, with first patient
Read more →MRKRMarker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 Houston, TX
Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 - February 25, 2019 - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation
Read more →MRKRMarker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility Houston, TX
Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility Houston, TX - February 15, 2019- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that it has formally relocated its corpora
Read more →MRKRThe Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 Houston, TX
The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 - January 15, 2019 - Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the
Read more →MRKRMarker Therapeutics Provides Updates of its Lead Clinical Programs Reports clinical data updates with MultiTAA T cells in lymphoma, multiple myeloma and acute lymphoblastic leukemia Reports completion of enrollment for T
Therapeutics Provides Updates of its Lead Clinical Programs Reports clinical data updates with MultiTAA T cells in lymphoma, multiple myeloma and acute lymphoblastic leukemia Reports completion of enrollment for TPIV200 Phase II study in ovarian cancer Reports interim immuno
Read more →MRKRSafety and efficacy of multi - TAA - T cells for Myeloma Premal Lulla , Ifigeneia Tzannou , George Carrum , Carlos A .
Safety and efficacy of multi - TAA - T cells for Myeloma Premal Lulla , Ifigeneia Tzannou , George Carrum , Carlos A . Ramos, Rammurti Kamble , Mrinalini Bilgi , Adrian P . Gee Shivani Mukhi , Betty Chung, Ayumi Watanabe, Manik Kuvalekar , Bambi Grilley , Malcolm K . Brenner, Hel
Read more →MRKRMarker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer Houston, TX
Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer Houston, TX - November 27, 2018 - Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced the appointment of Anthony H. Kim as its new Chief Financial Offi
Read more →MRKRThe Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60 th American Society of Hematology Annual Meeting --Three abstracts accepted, including oral presentation on multiple myeloma clinica
for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting --Three abstracts accepted, including oral presentation on multiple myeloma clinical data-- - November 27, 2018 - Marker Therapeutics, Inc. (NASDAQ:MRK
Read more →MRKRMarker Therapeutics, Inc. Announces New Executive Appointments Juan Vera, M.D., appointed Chief Development Officer and Board Director Ann Leen, Ph.D., appointed Chief Scientific Officer Ken Moseley, J.D. appointed Gener
Marker Therapeutics, Inc. Announces New Executive Appointments Houston, TX - October 23, 2018 - Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced the addition of four senior executives to its executive management team. Juan F
Read more →MRKRTAPIMMUNE AND MARKER THERAPEUTICS ANNOUNCE SUCCESSFUL CLOSING OF PREVIOUSLY ANNOUNCED MERGER AND FINANCING TapImmune Inc. changes name to Marker Therapeutics, Inc. To Commence Trading on NASDAQ Capital Market on Thursday
TAPIMMUNE AND MARKER THERAPEUTICS ANNOUNCE SUCCESSFUL CLOSING OF PREVIOUSLY ANNOUNCED MERGER AND FINANCING TapImmune Inc. changes name to Marker Therapeutics, Inc. To Commence Trading on NASDAQ Capital Market on Thursday, October 18, 2018 under Ticker Symbol "MRKR" Compl
Read more →MRKRAllison Mickey 713-798-4710 allison.huseman@bcm.edu www.bcm.edu/news From the labs to commercialization: Companies merge to implement Baylor College of Medicine-developed therapies for cancer HOUSTON - (
allison.huseman@bcm.edu From the labs to commercialization: Companies merge to implement Baylor College of Medicine-developed therapies for cancer HOUSTON - (August 8, 2018) - Despite major advances in cancer therapy, conventional cancer treatments continue to be associated w
Read more →MRKRTapImmune Announces Pricing of $70 Million Private Placement Financing Led by New Enterprise Associates (NEA) Financing to Close Concurrently with Close of Merger with Marker Therapeutics
Announces Pricing of $70 Million Private Placement Financing Led by New Enterprise Associates Financing to Close Concurrently with Close of Merger with Marker Therapeutics JACKSONVILLE, Florida, June 8, 2018 - TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology c
Read more →MRKRTapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform Transaction Adds Multi-Antigen Targeted Cell Therapy Platform to TapImmune's Peptide Vaccine Po
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform Transaction Adds Multi-Antigen Targeted Cell Therapy Platform to TapImmune's Peptide Vaccine Portfolio TapImmune Raises $5.1 million in Financing fr
Read more →MRKRTapImmune Appoints Peter Hoang as President and Chief Executive Officer
TapImmune Appoints Peter Hoang as President and Chief Executive Officer JACKSONVILLE, Florida, September 25, 2017 / TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women's cancers, today ann
Read more →MRKRTapImmune Inc. Enters into Definitive Agreements to Raise $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors
TapImmune Inc. Enters into Definitive $6.82 Million in a Private Placement from Accredited Investors and from the Exercise of Warrants by Existing Institutional Investors JACKSONVILLE, Florida, June 22, 2017 / TapImmune Inc. (Nasdaq Capital Market: TPIV), a clinical-stage i
Read more →MRKRTapImmune Announces Change in Management and Board of Directors
TapImmune Announces Change in Management and Board of Directors April 28, 2017, Jacksonville, FL,, TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for
Read more →MRKRTapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market JACKSONVILLE, Florida, September 15, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-bas
Read more →MRKRTapImmune Appoints Michael J. Loiacono as Chief Financial Officer Accomplished Financial Director & CFO of Public Companies
TapImmune Appoints Michael J. Loiacono as Chief Financial Officer Accomplished Financial Director & CFO of Public Companies August 25, 2016, Jacksonville, FL,, TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovativ
Read more →MRKRTapImmune Enters into Definitive Agreements to raise $8.5 Million from the Exercise of Outstanding Warrants and in a Private Placement from New Investors Company has Applied for Listing on Nasdaq Capital Market
TapImmune Enters into Definitive Agreements to raise $8.5 Million from the Exercise of Outstanding Warrants and in a Private Placement from New Applied for Listing on Nasdaq Capital Market JACKSONVILLE, Florida, August 11, 2016 / TapImmune Inc. (TPIV), a clinical-stage immuno-
Read more →MRKRTapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer
TapImmune Appoints Dr. John N. Bonfiglio as President and Chief Operating Officer JACKSONVILLE, Florida, July 19, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and
Read more →MRKRTapImmune Appoints Frederick G. Wasserman to its Board of Directors Accomplished Financial Director & CFO of Public Companies PR Newswire
TapImmune Appoints Frederick G. Wasserman to its Board of Directors Accomplished Financial Director & CFO of Public Companies JACKSONVILLE, Florida, January 27, 2016 JACKSONVILLE, Florida, January 27, 2016 /PRNewswire/ TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immunolo
Read more →MRKRU.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune's TPIV 200 in the Treatment of Ovarian Cancer Company preparing for Phase II ovarian cancer trial based on positive data in Mayo Clinic Phase I
U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune's TPIV 200 in the Treatment of Ovarian Cancer Company preparing for Phase II ovarian cancer trial based on positive data in Mayo Clinic Phase I trial JACKSONVILLE, Florida, December 9, 2015 JACKSONVILL
Read more →MRKRINTERNATIONAL CENTRE FOR DISPUTE RESOLUTION International Arbitration Tribunal TapImmune, Inc., Claimant, v. ICDR Case No. 50- 20- 1300- 0061 Michael Gardner, Respondent. FINAL AWARD I, THE UNDERSIGNED ARBITRATOR, having
INTERNATIONAL CENTRE FOR DISPUTE RESOLUTION International Arbitration Tribunal v. ICDR Case No. 50- 20- 1300- 0061 I, THE UNDERSIGNED ARBITRATOR, having been designated in accordance with the arbitration greement entered into between the above-named parties and dated May 8, 20
Read more →MRKRTapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ breast cancer. Results Meet Management's Highest Expectations. March 3 2014, Seattle WA , TapImmune Inc. (OTCQB: TPIVD) is pleased to report
TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ breast cancer. Results Meet Management's Highest Expectations. March 3 2014, Seattle WA, TapImmune Inc. (OTCQB: TPIVD) is pleased to report that analysis of the interim data from the first set of pat
Read more →MRKRand agree with the statements made by TapImmune regarding my resignations Sincerely, /s/ Denis Corin Denis Corin President, Acting Chief Financial Officer and Acting Principal Accounting Officer
This will serve as my resignation from the Board of Directors of TapImmune Inc. ("TapImmune") and from any position as an officer (including as President, Acting Chief Financial Officer and Acting Principal Accounting Officer) or employee of TapImmune Inc. These resignations do n
Read more →MRKRTapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation into a Vaccine to Treat HER2/neu Breast Cancer. Addition of Class I antigen provides new advance in development of HER2/neu vaccines.
TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation into a Vaccine to Treat HER2/neu Breast Cancer. Addition of Class I antigen provides new advance in development of HER2/neu vaccines. April 16, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has a
Read more →MRKRENTITLED ?TAPIMMUNE CLOSES $1.13 MILLION FUNDING: COMPANY RETIRES NOTES AND 11.2MM WARRANTS? DATED MARCH 1, 2011. exhibit99-1.htm CONTACTS: Glynn Wilson, Chairman & CEO Taplmmune Inc. (866) 359-7541 Investo
Glynn Wilson, Chairman & CEO Investor Relations (800) 953-3350 TapImmune Closes $1.13 Million Funding Company Retires Notes and 11.2MM Warrants Seattle WA, TapImmune Inc. (OTCBB: TPIV), is pleased to announce the closing of a $1.16M funding. On February 24, 2011, we entered
Read more →MRKRGlynn Wilson Chairman & CEO TapImmune Inc. 2815 Eastlake Avenue, Suite 300 Seattle, WA 98102
2815 Eastlake Avenue, Suite 300 Please accept this letter as formal notification that I hereby resign my positions as Chief Financial Officer and Member of the Board of Directors effective immediately.
Read more →MRKRGlynn Wilson, Chairman & CEO Taplmmune Inc. (866) 359-7541 Donald C. Weinberger/Adam Lowensteiner Wolfe Axelrod Weinberger Assoc. LLC Tel. (212) 370-4500 Fax (212) 370- 4505 TAPIMMUNE CLOS
Glynn Wilson, Chairman & CEO Donald C. Weinberger/Adam Lowensteiner Wolfe Axelrod Weinberger Assoc. LLC Tel. (212) 370-4500 Fax (212) 370- 4505 TAPIMMUNE CLOSES INSTITUTIONAL FINANCING TOTALING $1.53 MILLION Bellevue, WA, May 24, 2010 - TapImmune Inc. (OTCBB: TPIV) announced
Read more →MRKRTapImmune Inc. Executes a Securities Purchase Agreement for the Issuance of $1.53 million in Convertible Debt Bellevue, Washington
TapImmune Inc. Executes a Securities Purchase Agreement for the Issuance of $1.53 million in Convertible Debt Bellevue, Washington, May 18, 2010, TapImmune Inc. (OTCBB: TPIV), a Nevada corporation, announced today that the Company entered into a definitive purchase agreement on
Read more →MRKRTapImmune Inc. Signs R&D Collaboration Letter of Intent Agreement With Aeras Global TB Vaccine Foundation
Inc. Signs R&D Collaboration Letter of Intent Agreement With Aeras Global TB 2010 (GlobeNewswire) -- Wash., Feb. 1, 2010 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced that it has signed a Letter of Intent (LOI) with Aeras Global TB Vaccine Foundation to enter into
Read more →MRKRTapImmune Inc. Announces Acquisition of Core TAP Technologies and Intellectual Property from The University of British Columbia New Name to Reflect a New Direction and Independent Operation VANCOUVER, BC
TapImmune Inc. Announces Acquisition of Core TAP Technologies and Intellectual Property from The University of British Columbia New Name to Reflect a New Direction and Independent Operation VANCOUVER, BC, June 28, 2007 - TapImmune Inc., a biotechnology company specializing in t
Read more →MRKRGENEMAX CORP. APPOINTS KONSTANTINE SARAFIS AS CHIEF OPERATING OFFICER VANCOUVER, Canada, August 30th, 2004/ Canada NewsWire / -- GeneMax Corp. (OTC Bulletin Board: GMXX; Frankfurt: GX1) GeneMax announced today that Konst
GENEMAX CORP. APPOINTS KONSTANTINE SARAFIS AS CHIEF OPERATING OFFICER VANCOUVER, Canada, August 30th, 2004/ Canada NewsWire / -- GeneMax Corp. (OTC Bulletin Board: GMXX; Frankfurt: GX1) GeneMax announced today that Konstantine Sarafis has been appointed as its Chief Operating
Read more →Competitive Position
How MRKR ranks across every disease it competes inCompetitive Position is a premium feature
See how MRKR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial